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GSHThis study was designed to investigate the beneﬁcial effect of catechin in a model of Parkinson's disease.
Unilateral, intrastriatal 6-hydroxydopamine (6-OHDA)-lesioned rats were pretreated with catechin (10 and
30 mg/kg) by intraperitoneal (i.p.) injection 2 h before surgery and for 14 days afterwards. After treatments,
apomorphine-induced rotations, locomotor activity, working memory and early and late aversive memories
were evaluated. The mesencephalon was used to determine the levels of monoamines and measurement of
glutathione (GSH). Immunohistochemical staining was also used to evaluate the expression of tyrosine
hydroxylase (TH) in mesencephalic and striatal tissues. Catechin administration attenuated the increase in
rotational behavior and the decrease in locomotor activity observed in lesioned rats. Although catechin did
not rescue the impairment of late aversive memory, it protected the animals against 6-OHDA-induced working
memory deﬁcits. Furthermore, catechin treatment restored GSH levels, and signiﬁcantly increased dopamine
and DOPAC content, and TH-immunoreactivity in 6-OHDA-lesioned rats. Catechin protected 6-OHDA-lesioned
rats due to its antioxidant action, indicating that it could be useful as an adjunctive therapy for the treatment
of Parkinson's disease.
© 2013 Elsevier Inc. All rights reserved.1. Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disor-
der that is characterized by severe motor symptoms, such as tremor,
postural imbalance, slowness of movement and rigidity (Chase et al.,
1998). The neuropathology of PD is based on dopaminergic cell loss in
the nigrostriatal tract, with at corresponding decrease in striatal
dopamine content. Several factors that have been implicated in neuronal
degeneration in Parkinson's disease include mitochondrial dysfunction,
oxidative stress, excitotoxicity, genetic susceptibility, apoptosis, deﬁcient
neurotrophic support, and immune deﬁciency (Anglade et al., 1997;
Tatton et al., 2003; Tompkins et al., 1997).
There are several animal models used to study PD, and one of the
best known is the unilateral striatal injection of 6-hydroxydopamine
(6-OHDA), which leads to behavioral, biochemical, and pathological
changes that are typical of PD (Schober, 2004; Schwarting and Huston,
1996). These toxic effects are attributed to the formation of various
oxidants and free radicals, lipid peroxidation, depletion of reduced gluta-
thione (GSH), and mitochondrial complex I deﬁcits (Schober, 2004).+55 85 33668333.
rights reserved.Studies of patients with PD suggest that the characteristic clinical
symptoms of bradykinesia, such as rigidity and resting tremor, are
frequently accompanied by impairments of cognitive function. Studies
have shown that between 15% and 20% of PD patients develop a frank
dementia (Brown and Marsden, 1984), and this condition is an impor-
tant predictor of a poorer quality of life for these patients (Karlsen
et al., 1998; Schrag et al., 2000).
Green tea consumption is inversely correlated with the incidence of
Alzheimer's and Parkinson's disease (Mandel et al., 2008), and catechin,
which is the main component of green tea prepared from Camellia
sinensis, may be responsible for the alleged protective effect.
Currently, there is growing interest in studying the potential
neuroprotective effects of polyphenols due to their antioxidant, radical
scavenging and iron chelating properties (Youdim et al., 2002). Studies
using N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) have
shown that both green tea extract and epigallocatechin-3-gallate
(EGCG), isolated from C. sinensis, are able to prevent striatal dopamine
depletion in mice and dopaminergic neuron loss induced by this toxin
(Levites et al., 2001).
Here, the beneﬁcial neuroprotective effect of catechin on memory
and locomotor impairment was investigated in an experimental
model of PD. For this purpose, apomorphine-induced rotation, working
memory and aversivememory were evaluated. Furthermore, mesence-
phalic and striatal TH-immunoreactivity, GSH levels and monoamine
content in mesencephalic tissue were also determined.
2 M.D.A. Teixeira et al. / Pharmacology, Biochemistry and Behavior 110 (2013) 1–72. Materials and methods
2.1. Chemicals
6-Hydroxydopamine hydrochloride (6-OHDA), apomorphine
hydrochloride, and (+)-catechin hydrate were purchased from Sigma
Chemical Co., USA. All other reagents were of analytical grade.2.2. Animals
Young adult (3 months) male Wistar rats (200–250 g) were
obtained from the Animal House of the Federal University of Ceará
and were maintained at 23–25 °C, with 12 h light–12 h dark cycle and
standard diet and tap water ad libitum. All procedures in this study
were in agreement with the Guide of Care and Use of Laboratory
Animals from the US Health and Human Services Department, and
were approved by the ethics committee on animal experimentation of
the Federal University of Ceará (protocol number 29/05).2.3. Experimental procedure
Animals (n = 90) were randomly divided into six groups: Sham-
operated (SO), which received 0.2% ascorbate-saline solution into the
right striatum; sham-operated group treated with catechin (10 and
30 mg/kg); lesioned group (6-OHDA), which received 6-OHDA injection
(7 μg/μl per site, in a total concentration of 21 μg/3 μl); and lesioned-
group treated with catechin (10 and 30 mg/kg). Unilateral, intrastriatal
6-OHDA injection was performed through a 5 μl Hamilton® syringe on
anesthetized rats (ketamine 100 mg/kg and xylazine 20 mg/kg, i.p.)
using a stereotaxic apparatus (Stoelting, USA) at the following coordi-
nates (mm): site 1: L: −2.5, AP: +0.5, V: +5.0; site 2: L: −3, AP:
−0.5, V:+6,0; and site 3: L:−3.7, AP:−0.9, V:+6.5 from the bregma,
according to the Atlas of Paxinos and Watson (1986). Catechin was
intraperitoneally administered 2 h before surgery and daily for a period
of fourteen days post-surgery. The control groups received vehicle
(saline) at an equivalent volume. The behavioral experiments were
performed between the fourteenth and ﬁfteenth days. Following
behavioral studies, the animals were euthanized, and the mesencepha-
lon (n = 11/group) was collected and stored at−70 °C until use. Four
animals from each group were perfused with paraformaldehyde for
immunohistochemical studies.2.4. Rotational behavior
The animals were tested for rotational behavior after receiving
apomorphine hydrochloride (0.6 mg/kg, i.p.) for ﬁfteen days post-
surgery, at 1-day intervals, after the last catechin injection. Rotational
testing with apomorphine was conducted according to a previously
described method (Ungerstedt, 1971). Brieﬂy, animals were placed
inside a cylindrical container (33 cm diameter and 35 cm height),
and ipsilateral and contralateral rotations were counted for 60 min
in a quiet isolated room. The data are presented as the total number
of rotations towards both the ipsilateral and contralateral directions.2.5. Open ﬁeld test
Fourteen days after surgery, the rats were tested for locomotor
activity using an open ﬁeld apparatus, which consisted of a black acrylic
chamber (50 × 50 cm),with 50 cmhighwalls, and theﬂoorwas divided
into four squares of equal size (Broadhurst, 1957). Each rat was posi-
tioned in the center of the arena and allowed to explore freely. The num-
bers of crossings and rearings were scored for 5 min. The arena was
cleanedwith 20% ethyl alcohol to remove any odors before the next test.2.6. Y-Maze test
Fourteenth day after surgery, spatial workingmemory was assessed
by recording spontaneous alternation behavior in the Y-maze (Sarter
et al., 1988). The apparatus was a wooden, black Y-maze. Each arm of
the maze was 12 cm wide, 40 cm long, and had 35 cm high walls.
Each rat was placed at the end of one arm and allowed to move freely
through the maze during an 8 min session. The ability to alternate
requires the rat to remember which arms have already been visited.
Each experiment was scored, and the percentage of spontaneous alter-
nation was calculated using the following formula:
Spontaneous alternation %ð Þ ¼ alternation behavior
maximum alternations
 
 100
where alternation behavior is deﬁned as consecutive entries into each
of the three arms, without repetition, and maximum alternations are
the total number of arm entries, minus two.
2.7. Passive avoidance test
Fourteen days after surgery, aversive memory was assessed
according to DeNoble et al. (1986). We used a two-compartment
apparatus (50 × 22 × 27; length × width × height) from Ugo Basile,
Italy. In the acquisition trial, each ratwas placed individually in the light
compartment, and when the animal entered the dark compartment, a
foot shock of 0.5 mA was delivered through the grid ﬂoor. The latency
time to enter the dark compartment was measured, with a cutoff time
of 300 s (baseline). The animal was removed from the apparatus, and
the trial was repeated 15 min later, even for animals that reached the
cutoff time (short memory). Twenty four hours later, the retrieval trial
was performed in the same manner, but in this scenario, no animal
was shocked (late memory).
2.8. Determination of monoamine levels
For the measurement of noradrenaline (NE), dopamine (DA) and
their metabolite, 3,4-dihydroxyphenylacetic acid (DOPAC), content
using high-performance liquid chromatography (HPLC), mesencephalic
tissues (n = 6/group) were used. Homogenates (10%) were prepared
in 0.1 M HClO4. After centrifugation at 4 °C for 15 min at 15,000 rpm,
the supernatant was ﬁltered (0.2 μm, Millipore), and a 20 μl sample
was injected into a C18 column. The mobile phase was 0.163 M citric
acid (pH 3.0), containing 0.02 mM NaCl with 0.69 mM sodium
octanesulfonic acid (SOS) as the ion pairing reagent, 4% v/v acetonitrile
and 1.7% v/v tetrahydrofuran. NE, DA andDOPACwere electrochemically
detected, using an amperometric detector (Shimadzu, Japan). The
amount of monoamines was determined by comparison with freshly
prepared standards, and their concentrations were expressed as ng/mg
of tissue.
2.9. Measurement of glutathione (GSH) levels
Reduced glutathione (GSH) was determined according to the
method described by Sedlak and Lindsay (1968), with modiﬁcations.
Mesencephalons (n = 5/group) were homogenized in ice-cold phos-
phate buffer (50 mM, pH 7.4) to produce a 10% homogenate. Aliquots
(500 μl) of tissue homogenate were mixed with 400 μl of distilled
water and 100 μl of 50% trichloroacetic acid (w/v) in Eppendorf tubes,
and the tubes were centrifuged at 3000 ×g for 15 min. The each super-
natant (330 μl) was then mixed with 666 μl of Tris (40 mM) and EDTA
(20 mM) buffer (pH 8.9) and 17 μl of 5,5′-ditiobis (2-nitrobenzoic acid)
(DTNB 10 mM). The absorbance was measured at 412 nm within
5 min. The GSH concentration (μg/g of wet tissue) was computed
from a standard curve.
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Fig. 1. Effects of catechin (10 and 30 mg/kg, i.p.) on apomorphine-induced (0.6 mg/kg,
i.p.) rotational behavior (A) and exploration activity (B) in 6-OHDA-lesioned rats.
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Four rats from each group were anesthetized with sodium pento-
barbital (50 mg/kg, i.p.) and the tissues were ﬁxed by transcardial
perfusionwith 0.1 Mphosphate-buffered saline (PBS, pH 7.2), followed
by 4% paraformaldehyde (PAF) in PBS. The brains were removed,
post-ﬁxed in 4% PAF for 24 h and cryoprotected with 30% sucrose/
0.1 M phosphate buffer. The brains were embedded in Tissue-Tek
(Sakura-Americas, USA), frozen at−21 °C and cut into 50 μm coronal
sections using a cryostat. Nigral (substantia nigra pars compacta) and
striatal slices were collected in series (300 μm interval), and the slices
were stored in 24-well plates as free-ﬂoating sections in PBS containing
0.01% NaN3. The sections were rinsed three times for 5 min in PBS, and
endogenous peroxidase was inhibited by incubating the sections in 3%
H2O2 in PBS, for 1 h at RT. Slices, were permeabilized and blocked
with PBS containing 1% Triton X-100 and 10% normal goat serum
(NGS), for 1 h at RT. The sections were incubated in primary antibody
(anti-TH rabbit, 1:500, Millipore) for 48 h at 4 °C, rinsed three times
for 10 min in PBS and subsequently incubated with avidin–biotin–
horseradish peroxidase conjugate (ABC Staining System, Santa Cruz
Biotechnology) for 30 min. After washing, the slides were incubated
with biotinylated goat anti-rabbit secondary antibody, diluted 1:500
in blocking solution. The color was developed using DAB as a chromo-
gen. The sections were mounted in Entellan (Merck, Germany), cover
slipped and visualized under a microscope. Eight sections per animal
(Olympus BX41 microscope equipped with an Olympus DP71 camera)
were analyzed to obtain a rostrocaudal sampling of the striatum, and
the intensity of the TH immunoreactivity was measured by semi-
quantitative densitometric analysis using an image-analysis program
(Image J software, NIH, MD, USA). The number of TH-positive neurons
in the SNpcwas counted using theMBF Image J version (NIH,MD, USA).A: Two weeks after 6-OHDA striatal injection, the number of net ipsi and contralateral
rotations was counted for 60 min. Data are reported as the means ± SEM of 6 to 10
animals for each group. * vs. Sham-operated, ** vs. 6-OHDA (ANOVA and Tukey's test).
B: Two weeks after 6-OHDA striatal injection, the number of crossings and rearings was
counted for 5 min. Data are reported as the means ± SEM of, 6 to 10 animals. * vs.
Sham-operated, ** vs. 6-OHDA (ANOVA and Tukey's test).2.11. Statistical analysis
Data are presented as the means ± SEM, and statistical signiﬁcance
was analyzed by one-way ANOVA, followed by Tukey's post-hoc test.3. Results
3.1. Neuroprotective effect of catechin against 6-OHDA-induced rotational
behavior
Two weeks after intrastriatal injection of 6-OHDA, rats exhibited
rotational behavior towards the opposite side of the lesion (contralateral
rotation) after apomorphine administration. Signiﬁcant increases in the
number of apomorphine-induced rotations were observed in the
6-OHDA-lesioned group compared to the sham-operated group (SO =
0.0; 6-OHDA = 76.3 ± 28.5, p b 0.05). Catechin signiﬁcantly reversed
this abnormal motor behavior (Cat10 + 6-OHDA = 11.7 ± 5.9;
Cat30 + 6-OHDA = 0.8 ± 0.5), and the observed values were very
close to those of the SO group (Fig. 1A).3.2. Effect of catechin on exploratory activity in 6-OHDA-lesioned rats
Wedid not observe a signiﬁcant decrease in the number of crossings
in 6-OHDA-lesioned rats, but we observed a signiﬁcant decrease in
the number of rearings, which evaluates the vertical exploratory
activity. Catechin treatment (10 mg/kg) signiﬁcantly protected the an-
imals against vertical exploratory activity deﬁcits induced by 6-OHDA
(no of crossings: SO = 21.1 ± 3.7; 6-OHDA = 14.2 ± 0.8; Cat10 +
6-OHDA = 24.5 ± 2.4; Cat30 + 6-OHDA = 21.1 ± 3.7; no of rearings:
SO = 10.3 ± 2.6; 6-OHDA = 5.7 ± 0.9; Cat10 + 6-OHDA = 17.5 ±
2.3, p b 0.05, ANOVA and Turkey's test) (Fig. 1B).3.3. Effect of catechin on working memory in 6-OHDA-lesioned rats
Fig. 2A illustrates the effect of 6-OHDA-lesion on working memory.
Rats exposed to 6-OHDA exhibited deﬁcits in working memory
(decreases of spontaneous alternations), and catechin signiﬁcantly
reversed these memory deﬁcits (% spontaneous alternations: SO =
70.8 ± 5.1%; 6-OHDA = 50.1 ± 9.8%; Cat10 + 6-OHDA = 77.6 ±
2.1%; and Cat30 + 6-OHDA = 80.4 ± 5.7%, p b 0.05).
3.4. Effect of catechin on aversive memory in 6-OHDA-lesioned rats
Only late aversive memory was signiﬁcant impaired in 6-OHDA-
lesioned rats compared to the sham operated group (latency: SO =
266.5 ± 33.4 s; 6-OHDA = 106.5 ± 29.6 s, p b 0.05). No memory
improvement was observed in lesioned animals after catechin treat-
ment on this type of memory (Fig. 2B).
3.5. Effect of catechin on monoamine levels in 6-OHDA-lesioned rats
6-OHDA caused a signiﬁcant decrease in mesencephalic dopamine,
noradrenaline and DOPAC content. Catechin treatment (10 and
30 mg/kg) protected animals from the observed decrease in dopamine
and noradrenaline, but not DOPAC content (Table 1).
3.6. Effect of catechin on GSH levels in 6-OHDA-lesioned rats
We observed a signiﬁcant decrease in GSH levels in themesenceph-
alon tissue of 6-OHDA-lesioned rats compared to the sham-operated
group (SO = 0.14 ± 0.01; 6-OHDA = 0.06 ± 0.00, p b 0.05). Catechin
SO
6-O
HD
A
Ca
t 1
0+
6-O
HD
A
Ca
t 3
0+
6-O
HD
A
Ca
t 1
0
Ca
t 3
0
0
20
40
60
80
*
**
**
sp
on
ta
ne
ou
s 
al
te
rn
at
io
ns
 (%
)
SO
6-O
HD
A
Ca
t10
+6
-O
HD
A
Ca
t30
+6
-O
HD
A
Ca
t 1
0
Ca
t 3
0
0
50
100
150
200
250
300
Trail
Early memory
Late memory
*
La
te
nc
y 
(s)
A
B
Fig. 2. Effects of catechin (10 and 30 mg/kg) onworking (A) and aversive (B)memories in
6-OHDA-lesioned rats. A: Two weeks after 6-OHDA striatal injection, the percentage of
spontaneous alternations was counted for 8 min. B: Two weeks after 6-OHDA striatal
injection, the latency time to enter the dark side of the passive avoidance apparatus was
registered over 300 s. Data are reported as the means ± SEM of 6 to 10 animals. * vs.
Sham-operated, ** vs. 6-OHDA (ANOVA and Tukey's test).
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Fig. 3. Effects of catechin (10 and 30 mg/kg) on glutathione (GSH) levels in the mesen-
cephalon tissue of 6-OHDA-lesioned rats. Data are reported as the means ± SEM of 6
to 10 animals. * vs. Sham-operated, ** vs. 6-OHDA (ANOVA and Tukey's test).
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(Cat10 + 6-OHDA = 0.18 ± 0.02 μg/g; Cat30 + 6-OHDA = 0.17 ±
0.02 μg/g tissue, p b 0.05) (Fig. 3).
3.7. Effect of catechin on tyrosine hydroxylase immunoreactivity in the
striatal and mesencephalic tissues of 6-OHDA-lesioned rats
Signiﬁcant decreases in the area of TH immunoreactivity were
observed in the ipsilateral striatum of 6-OHDA-lesioned rats compared
to the sham-operated group (OD values: SO = 0.66 ± 0.08; 6-
OHDA = 0.13 ± 0.06, p b 0.05). In the substantia nigra pars compacta
(SNpc), a signiﬁcant decrease in the number of TH-positive cells was
observed (SO = 151.0 ± 13.6; 6-OHDA = 55.0 ± 15.0, p b 0.05).
Catechin (30 mg/kg) decreased the loss of TH immunoreactivity
(0.32 ± 0.10, p b 0.05) and increased the number of TH-positive cellsTable 1
Effects of catechin (10 and 30 mg) on monoamine levels (ng/mg tissue) in the rat
mesencephalon after the formation of 6-OHDA-induced lesion.
Group DA NE DOPAC
SO 1037 ± 62 1886 ± 151 143 ± 53
6-OHDA 359 ± 83⁎ 369 ± 82⁎ 42 ± 15⁎
Cat 10 + 6-OHDA 615 ± 94⁎⁎ 901 ± 143⁎⁎ 110 ± 33
Cat 30 + 6-OHDA 820 ± 140⁎⁎ 883 ± 76⁎⁎ 64 ± 10
DA: dopamine, NE: noradrenaline, DOPAC: 3,4 dihydroxyphenylacetic acid. Animals
received catechin (10 and 30 mg/kg, i.p.) 2 h before surgery and daily for 14 days.
Data are reported as the means ± SEM of 6 animals/group. p b 0.05 (ANOVA and the
Tukey's test).
⁎ vs. sham-operated.
⁎⁎ vs. 6-OHDA.(106.8 ± 11.2, p b 0.05) in lesioned rats (Fig. 4C), suggestive of
neuroprotective action. The contralateral hemisphere was not affected
by injection, and no signiﬁcant differences were observed between
the control and treated groups.
4. Discussion
Anti-parkinsonian agents used in PD treatment partially relieve the
symptoms of this disease, but they are not able to block dopaminergic
neurodegeneration; thus, the disease continues to progress. Currently,
there is a great demand for new therapies that prevent neuronal
death. New therapeutic strategies for PD must identify compounds
that are neuroprotective and able to cross the blood–brain barrier to
produce the desired effects without causing adverse side effects. Cate-
chin has emerged as a capable neuroprotective candidate that possesses
antioxidant properties and has the ability to cross the blood–brain
barrier (Nakagawa and Miyazama, 1997). In this study, the protective
effect of catechin against 6-OHDA-induced neuronal damage and
memory deﬁcits was investigated. Our results demonstrated that intra-
peritoneal administration of catechin, a constituent of green tea
(C. sinensis), over a 2-week time period signiﬁcantly attenuated the 6-
OHDA-induced behavioral abnormalities. The stereotaxic injection of
6-OHDA into the substantia nigra, medial forebrain bundle, or striatum,
or peripheral administration in neonatal rats induced degeneration of
the nigrostriatal pathway and striatal dopamine depletion, closelymim-
icking events that occur in PD (Jenner, 2008). The major neurotoxic
mechanism of 6-OHDA is thought to involve radical oxygen species
generated by autoxidation (Soto-Otero et al., 2000). Motor function
abnormalitywas veriﬁedby administering apomorphine, a dopaminergic
agonist, to 6-OHDA-lesioned rats. In this condition, apomorphine induces
contralateral rotation behavior, reﬂecting an upregulation of striatal
dopaminergic receptors on the lesioned site due to dopamine depletion
(Ungerstedt, 1971). We showed that catechin decreased the number of
contralateral rotations of lesioned rats, suggestive of a neuroprotective
effect.
One possible mechanism underlying the effectiveness of catechin
in this study may involve its catechol-like structure, as catechol-
containing compounds are potent radical scavengers and chelators
of ferric ions (Gassen and Youdim, 1997; Guo et al., 1996; van Acker
et al., 1996). Catechin also displayed antioxidant activity in our
study by increasing GSH activity. Epigallocatechin-3-gallate (EGCG),
another major polyphenolic compound present in green tea, was
shown to increase the cellular GSH pool by elevating the mRNA
expression level of gamma-glutamylcysteine ligase, the rate limiting
enzyme for glutathione biosynthesis (Kim et al., 2009). These authors
concluded that EGCG might elicit protective effects by augmenting the
cellular antioxidant capacity. More recently (Yu et al., 2010), EGCG
was shown to block glutamate excitotoxicity, and according to this
Fig. 4. Representative photomicrographs of coronal sections showing (A) TH immunostaining in the striatum and (B) TH-positive cells in the SNpc (4× objective, Olympus BX41
microscope equipped with an Olympus DP71 camera). Higher magniﬁcation is shown in the small box (40× objective). (C) Semi-quantitative analysis of TH immunoreactivity
in the striatum and (D) the number of TH-positive neurons in the SNpc were assessed using optical densitometry. Analyses were made in serial coronal sections (50 μm thick
and 300 μm apart) that were representative of the ipsilateral striatum or SNpc. *p b 0.05 vs. SO group, **p b 0.05 vs. 6-OHDA group. Data are expressed as the mean ± SEM
(one way ANOVA followed by Tukey's post hoc test).
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activity.
We have previously shown that catechin prevents 6-OHDA-induced
oxidative cell damage in primary cultures of rat mesencephalic cells.
After the exposure of these cells to 6-OHDA, the cultures showed a
marked decrease in cell viability, disturbances in lipid peroxidation,
and increased NO generation. Catechin treatment signiﬁcantly attenu-
ated 6-OHDA-induced cell death. Our results suggest that catechin
elicited its effects by inhibiting lipid peroxidation, without interfering
on the 6-OHDA-induced increase in nitrite/nitrate production (Nobre-
Júnior et al., 2003). Chan et al. (2002) showed that in cultured rat
brain astrocytes, the activity of SOD (Cu, Zn-SOD and Mn-SOD sub-
types) was markedly increased after incubation with catechin. Thus,
interfering with the SOD pathway may also have contributed to the
neuroprotective effect of catechin. Other reports have also demonstrated
the antioxidant activity of catechins (Babu et al., 2006; Skrzydlewska
et al., 2002a, 2002b).
Another mechanism that could be involved in the neuroprotective
effect of catechin is its anti-apoptotic activity. Catechins, such as
epigallocatechin gallate (EGCC), have been shown to provide
neuroprotection by inactivating pro-apoptotic genes (Williams and
Spencer, 2012; Renno et al., 2012). It was previously shown (Schroeder
et al., 2009) that EGCG protected neurons from apoptosis induced by
mitochondrial oxidative stress through their action as free radicalscavengers. Thus the anti-apoptotic action of catechin may have been
responsible in part for the neuroprotective effect observed by us, but
this mechanism of action from catechin was not investigated in our
study.
A number of intracellular signaling pathways, including mitogen-
activated protein kinases (Chen et al., 2000), protein kinase C
(Levites et al., 2003), phosphatidylinositol-3-kinase (PI-3 kinase)-Akt
(Koh et al., 2003), NOS isoforms and preservation of mitochondrial
complex activity and integrity (Sutherland et al., 2005), have been de-
scribed to be involved in ECGC-induced neuronal protection. Oxidative
stress seems to be a major stimulus for the MAPK cascade, which could
ultimately lead to cell survival/death. The MAPK pathways play crucial
roles as transducers of extra-cellular stimuli via a series of intracellular
phosphorylation cascades. These pathways exert important functions in
neuronal protection against a variety of insults and are essential to cell
survival (Xia et al., 1995).
The major clinical symptoms of PD are body rigidity, hypokinesia,
and postural instability linked with trembling extremities. PD clinical
features also comprise non-motormanifestations, themost important of
which is dementia. In approximately 40% of patients, PD is complicated
by cognitive impairment (Papapetropoulos et al., 2004; Williams-Gray
et al., 2006). Moreover, in addition to age, dementia is an independent
predictor of mortality, whereas the age of PD onset and severity of neu-
rological symptoms are not (Hughes et al., 2004). Patients with PD have
6 M.D.A. Teixeira et al. / Pharmacology, Biochemistry and Behavior 110 (2013) 1–7two components of cognitive dysfunction: generalized subcortical
dementia (PDsCD) and a hypothesized, overlapped pattern, suggesting
speciﬁc prefrontal dysfunction. PDsCD is considered to be multifactorial
and comprises the highly selective loss of dopamine (DA) neurons in the
SN. Furthermore, losses also occur in other nervous cells, such as the
norepinephrine neurons in the locus ceruleus and in the dorsal motor
nucleus of the vagus, the nucleus basalis ofMeynert (with a pronounced
depletion of cholinergic neurons), epinephrine neurons in the rostral
ventral lateral medulla, and serotonin neurons in the dorsal raphe
nuclei (Rinne et al., 2000; Vale, 2008; Warren et al., 2005). In addition,
frontal-like deﬁcits on various tests of working memory have been
reported in PD, reﬂecting the effect of striatal dopamine depletion
interrupting the normal ﬂow of information through fronto-striatal cir-
cuitry in these patients (Owen et al., 1998).
Studies carried out with 1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine (MPTP), a neurotoxin used to mimic PD in primates and
rodents, have shown both procedural and working memory impair-
ments in rats (Bellissimo et al., 2004; Braga et al., 2005; Da Cunha
et al., 2007; Gevaerd et al., 2001; Prediger et al., 2006; Reksidler et al.,
2007). Moreover, 6-OHDA, when injected in SNc, was shown to cause
alterations in both the cued and spatial memory versions of the water
maze test, reﬂecting memory deﬁcits similar to those observed in the
early phase of PD (Ferro et al., 2005; Lindner et al., 1999). Thus, we
showed that catechin restored the content of dopamine and noradren-
aline in themesencephalon, and this effectmay be indirectly associated
with the neuroprotective effect of the drug. Alternatively, by directly
increasing the release of dopamine, Jeong et al. (2007) showed that
EGCC increases the ﬁring rate of substantia nigra dopaminergic neurons
in rats, and this action could explain the neuroprotective effect of cate-
chin observed in this study.
Previous studies have suggested that spatial/relational and cued task
learning are independently processed by different brain structures
(Packard et al., 1989; Packard and McGaugh, 1992; White and
McDonald, 2002). Thus, it has been shown that spatial learning in rats
is critically dependent on the integrity of the hippocampus, but not of
the dorsal striatum, whereas cued task learning is dependent on the
integrity of the dorsal striatum. In the early stages of PD, when the
nigrostriatal pathway is damaged, patients present impaired learning
of habit tasks but retain the ability to form new episodic memories
(Dubois and Pillon, 1997; Knowlton et al., 1996). Between 15% and
20% of PD patients develop a frank dementia (Brown and Marsden,
1984), and less severe cognitive impairment is a well-recognized
feature early in the disease that has been shown to be an important
predictor for quality of life (Karlsen et al., 1998; Schrag et al., 2000).
The patterns of cognitive impairment observed in the early stages of
PD resemble those produced by frontal lobe damage, which include
deﬁcits in executive functions. In PD, several aspects of executive dys-
function have been shown to be extremely sensitive to the effects of
controlled L-dopa withdrawal (Lange et al., 1992), suggesting that
these deﬁcits are predominantly due to a dopaminergic substrate.
We observed working and late aversive memory deﬁcits on rats
exposed to 6-OHDA, and a protective effect of catechin on working
memory deﬁcits. Perry et al. (2004) showed that intranigral 1-methyl-
phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration, a dopami-
nergic toxin, induced aversive memory deﬁcits in rats tested in the
active avoidance task. In a task which required active avoidance of an
aversive stimulus cued by a conditioned stimulus, MPTP produced
impaired retention (Georgiev and Kambourova, 1991). Haque et al.
(2006) also showed that catechin improved reference and working
memory-related learning ability. We did not observe any effect of cate-
chin on late aversive memory, as assessed using the passive avoidance
test. Pu et al. (2007) showed that catechin did not improve spatial
memory impairment in the 8-arm radial maze task or decrease cerebral
ischemia-induced neuronal death in the hippocampal CA1 area in rats.
However, the data presented in the literature is contradictory and in-
conclusive as far as this issue is concerned. Other studies have reportedthat catechin prevented spatial learning and memory impairments in
senescence-accelerated mouse prone-8 mice (Li et al., 2009b) and
C57BL/6J mice (Li et al., 2009a) in the Morris water maze.
Here, we show that the neuroprotective effect of catechin against
motor and memory deﬁcits in the 6-OHDA model of PD, supporting a
potential neural basis for the beneﬁcial effect of catechins on diseases
where oxidative stress andmitochondrial dysfunction are involved, and
reconﬁrming the potential of antioxidants as a coadjuvant treatment
for neurodegenerative disease.
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